Treatment of Ovarian Cancer in Carcinosarcoma (Malignant Mixed Müllerian Tumor, MMMT)
Carcinosarcoma of the ovary — also known as malignant mixed Müllerian tumor (MMMT) — is a rare, aggressive histologic subtype of ovarian cancer that presents distinct clinical management considerations compared with more common epithelial ovarian malignancies.
Clinical scenario
This protocol addresses ovarian cancer arising as carcinosarcoma (MMMT). The biphasic nature of this tumor — combining carcinomatous and sarcomatous elements — informs the choice of systemic treatment strategy.
Adjuvant treatment approach
The preferred approach involves intravenous platinum-based combination chemotherapy administered in defined cycles. Additional systemic regimen options incorporating other cytotoxic agents are recognized alternatives.
Full regimen details, agent combinations, sequencing, and the complete set of alternatives are available in the structured protocol below.
References
- Carcinosarcoma (malignant mixed Müllerian tumor [MMMT])
- IV carboplatin/paclitaxel every 3 weeks (preferred)
- Carboplatin/Ifosfamide
- Cisplatin/Ifosfamide/Mesna
- Ifosfamide/Mesna/Paclitaxel
View source ↗